Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey
Background/Aim. We evaluate the impact of combined pentoxifylline and high-dose vitamins E to standard antiviral treatment on RBV-induced haemolytic anaemia. Patients and Methods. Selected 200 naïve chronic HCV patients, were randomized to receive either the standard antiviral therapy (peginterfero...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Hepatology |
| Online Access: | http://dx.doi.org/10.4061/2011/530949 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565623876485120 |
|---|---|
| author | M. Assem M. Yousri |
| author_facet | M. Assem M. Yousri |
| author_sort | M. Assem |
| collection | DOAJ |
| description | Background/Aim. We evaluate the impact of combined pentoxifylline and high-dose vitamins E to standard antiviral treatment on RBV-induced haemolytic anaemia. Patients and Methods. Selected 200 naïve chronic HCV patients, were randomized to receive either the standard antiviral therapy (peginterferon α-2b and RBV) plus pentoxifylline (800 mg) and high-dose vitamin E (1000 iu) daily (combined group) or received standard antiviral therapy plus placebo only (control group). They were followed up during treatment course and for 6 months posttreatment to assess the occurrence of anaemia and virological response, respectively. Results. RBV dose modification due to anaemia were significantly less in combined group (8.5 versus 21.5%.
P<.05).Withdrawal, secondary to sever anemia (Hb<8.5 gm%), was recorded only in 6 (28.6%) patients of the control group. Both (ETR) and (SVR) were significantly higher in combined group than control group by both intention-to-treat analysis (71 versus 56%, P<.05 and 66 versus 49%, P<.05) and per-protocol analysis (85.5 versus 70.9%,
P<.05 and 79.5 versus 62%, P<.05). Conclusion. Pentoxifylline and vitamin E can ameliorate RBV-associated haemolysis; improve compliance and virologic clearance when combined with the standard antiviral therapy in patients with chronic hepatitis C. |
| format | Article |
| id | doaj-art-037c1523e0394875a36a7bec1138b8a0 |
| institution | Kabale University |
| issn | 2090-3448 2090-3456 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hepatology |
| spelling | doaj-art-037c1523e0394875a36a7bec1138b8a02025-02-03T01:07:03ZengWileyInternational Journal of Hepatology2090-34482090-34562011-01-01201110.4061/2011/530949530949Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian SurveyM. Assem0M. Yousri1Departments of Hepatology and Gastroenterology, National Liver Institute, Monoufiya University, Sheben Al kom 3211, EgyptDepartments of Hepatology and Gastroenterology, National Liver Institute, Monoufiya University, Sheben Al kom 3211, EgyptBackground/Aim. We evaluate the impact of combined pentoxifylline and high-dose vitamins E to standard antiviral treatment on RBV-induced haemolytic anaemia. Patients and Methods. Selected 200 naïve chronic HCV patients, were randomized to receive either the standard antiviral therapy (peginterferon α-2b and RBV) plus pentoxifylline (800 mg) and high-dose vitamin E (1000 iu) daily (combined group) or received standard antiviral therapy plus placebo only (control group). They were followed up during treatment course and for 6 months posttreatment to assess the occurrence of anaemia and virological response, respectively. Results. RBV dose modification due to anaemia were significantly less in combined group (8.5 versus 21.5%. P<.05).Withdrawal, secondary to sever anemia (Hb<8.5 gm%), was recorded only in 6 (28.6%) patients of the control group. Both (ETR) and (SVR) were significantly higher in combined group than control group by both intention-to-treat analysis (71 versus 56%, P<.05 and 66 versus 49%, P<.05) and per-protocol analysis (85.5 versus 70.9%, P<.05 and 79.5 versus 62%, P<.05). Conclusion. Pentoxifylline and vitamin E can ameliorate RBV-associated haemolysis; improve compliance and virologic clearance when combined with the standard antiviral therapy in patients with chronic hepatitis C.http://dx.doi.org/10.4061/2011/530949 |
| spellingShingle | M. Assem M. Yousri Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey International Journal of Hepatology |
| title | Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey |
| title_full | Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey |
| title_fullStr | Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey |
| title_full_unstemmed | Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey |
| title_short | Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Haemolytic Anaemia in Chronic Hepatitis C Patients: An Egyptian Survey |
| title_sort | impact of pentoxifylline and vitamin e on ribavirin induced haemolytic anaemia in chronic hepatitis c patients an egyptian survey |
| url | http://dx.doi.org/10.4061/2011/530949 |
| work_keys_str_mv | AT massem impactofpentoxifyllineandvitamineonribavirininducedhaemolyticanaemiainchronichepatitiscpatientsanegyptiansurvey AT myousri impactofpentoxifyllineandvitamineonribavirininducedhaemolyticanaemiainchronichepatitiscpatientsanegyptiansurvey |